Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use

JAMA. 2003 Feb 19;289(7):885-8. doi: 10.1001/jama.289.7.885.

Abstract

Context: Previous surveillance studies have documented increasing rates of antimicrobial resistance in US intensive care units (ICUs) in the early 1990s.

Objectives: To assess national rates of antimicrobial resistance among gram-negative aerobic isolates recovered from ICU patients and to compare these rates to antimicrobial use.

Design and setting: Participating institutions, representing a total of 43 US states plus the District of Columbia, provided antibiotic susceptibility results for 35 790 nonduplicate gram-negative aerobic isolates recovered from ICU patients between 1994 and 2000.

Main outcome measures: Each institution tested approximately 100 consecutive gram-negative aerobic isolates recovered from ICU patients. Organisms were identified to the species level. Susceptibility tests were performed, and national fluoroquinolone consumption data were obtained.

Results: The activity of most antimicrobial agents against gram-negative aerobic isolates showed an absolute decrease of 6% or less over the study period. The overall susceptibility to ciprofloxacin decreased steadily from 86% in 1994 to 76% in 2000 and was significantly associated with increased national use of fluoroquinolones.

Conclusions: This study documents the increasing incidence of ciprofloxacin resistance among gram-negative bacilli that has occurred coincident with increased use of fluoroquinolones. More judicious use of fluoroquinolones will be necessary to limit this downward trend.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use*
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology
  • Drug Resistance, Bacterial*
  • Drug Utilization / trends
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Intensive Care Units / statistics & numerical data
  • Intensive Care Units / trends*
  • Microbial Sensitivity Tests
  • United States

Substances

  • Anti-Infective Agents
  • Ciprofloxacin